Multitude Therapeutics Inc.
Multitude Therapeutics Inc.
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-08-27 | NCT07474727 | |
| Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-08-10 | NCT07718737 | |
| AMT-116 in Combination With AK112 in Patients With Lung Cancer | Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting | Phase 1 / Phase 2 | 2026-08-10 | NCT07590531 | |
| AMT-676 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Early phase 1 | 2026-05-18 | NCT06400485 | |
| AMT-253 in Patients With Advanced Solid Tumours | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-09-05 | NCT06209580 | |
| AMT-116 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-08-17 | NCT05725291 | |
| AMT-116 in Patients with Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-01-17 | NCT06782334 |